OAB-WRAP^®: Focus on Early,
Evidence-Based Management of OAB—

The Foundation Role of Muscarinic Receptor Antagonists

HealthWRAP CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Release Date:

November 5, 2008

Expiration Date:

November 5, 2010

Intended Audience:

This HealthWRAP is designed for all physician specialists and primary care providers who manage patients with urinary tract disorders, especially those with overactive bladder and related conditions. These clinical disciplines include, but are not limited to: urological specialists, specialists in urologic gynecology, primary care physicians, geriatricians, long-term care directors, women’s health specialists, nurse practitioners, geriatric nurse practitioners, pharmacists and physician assistants.

Registration:

Enrollment for this HealthWRAP is complimentary, and clinicians are invited to participate in this CME-certified HealthWRAPs and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

Supported by an independent
educational grant from
Astellas Pharma.
 

Accreditation Statement for Jointly-Sponsored Programs:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty and Provider Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty:

David Staskin, MD
Associate Professor
Department of Urology
Tufts University Medical Center
Boston, Massachusetts

Faculty Disclosures:

Dr. Staskin reports that he has received funding as an investigator for Allergan, Pfizer and Watson. He has also received consulting fees from Allergan, Astellas, Pfizer and Watson.

Educational Objectives:

After viewing this program, physicians, pharmacists, and other healthcare providers will:

• Learn to screen patients for urinary tract disorders, including overactive bladder.
• Learn how to confirm the diagnosis of overactive bladder, and learn the appropriate sequence and use historical of historical features and laboratory modalities used to confirm the diagnosis.
• Learn how to use pharmacologic agents, with a focus on antimuscarinic agents.
• Learn evidence-based approaches to managing urinary tract, with a special focus on differentiating safety, efficacy, and pharmacologic properties of available therapeutic agents.
• Learn how to counsel patients with overactive bladder and guide them in multimodal measures that improve long-term urinary tract health.
• Learn how to implement a systematic approach to diagnostic assessment of patients with urinary frequency, urgency, and related symptoms.
• Learn how landmark trials and analyses focusing on overactive bladder should guide pharmacologic therapy.
  

Disclaimer:

Copyright © 2008 by Pharmatecture, LLC. All rights reserved. Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this HealthWRAP reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this HealthWRAP is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this HealthWRAP is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This HealthWRAP is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This HealthWRAP is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © 2008 All rights reserved